TXMD

TXMD to present at Stifel 2020 Virtual Healthcare Conference on Tuesday, Nov. 17 at 9:20 a.m. ET; see details for live webcast

TherapeuticsMD, Inc. (NASDAQ:TXMD) just released its latest third-quarter results and things are looking bullish...

TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of approximately 23.4 million shares of its common stock for gross proceeds of $30 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by TherapeuticsMD. The offering is expected to close on or about November 12, 2020, subject to customary closing conditions. In addition, TherapeuticsMD has granted the underwriter a 30-day option to purchase up to approximately 3.5 million additional shares of common stock.

TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 28.57% and 9.47%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Therapeutics MD (TXMD): Q3 GAAP EPS of -$0.12 beats by $0.01.Revenue of $19.34M (-18.5% Y/Y) beats by $3.9M.Gross margin increased to 83%, compared to 59% for the quarter ended June 30,

During Q2, TherapeuticsMD (NASDAQ: TXMD) brought in sales totaling $10.70 million. However, earnings decreased 11.55%, resulting in a loss of $45.04 million. TherapeuticsMD collected $12.25 million in revenue during Q1, but reported earnings showed a $50.92 million loss.Why ROCE Is Significant Changes in earnings and sales indicate shifts in TherapeuticsMD's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q2, TherapeuticsMD posted an ROCE of 0.48%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.View more earnings on TXMDROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows TherapeuticsMD is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.In TherapeuticsMD's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.Q2 Earnings Recap TherapeuticsMD reported Q2 earnings per share at $-0.19/share, which did not meet analyst predictions of $-0.17/share.See more from Benzinga * Click here for options trades from Benzinga * Return On Capital Employed Overview: Apple * Return On Capital Employed Overview: Twilio(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&p=1&f=G&l=50&d=PTXT&S1=TherapeuticsMD&OS=TherapeuticsMD&RS=TherapeuticsMD

TherapeuticsMD (TXMD) +6.1% PM, believes that the company is on track to meet or exceed Q3 total net revenue consensus of $15.1M.For the ANNOVERA product, orders to wholesalers, retail pharmacies and online distributors across